What Changed
Scribe Therapeutics filed an S-1 registration statement on July 23, 2026. The biotech gene-editing company is preparing to go public with an IPO expected within 90 to 120 days. No pricing range or share count has been disclosed yet, but comparable biotech IPOs in 2026 have priced between $18 and $24 per share with initial market caps of $1.2B to $2.8B.
The Numbers That Matter
| Metric | Scribe Therapeutics | Comparable Biotech IPO Range (2026) | Post-IPO Day 1 Volatility (Median) |
|---|---|---|---|
| Expected Market Cap | Not disclosed | $1.2B to $2.8B | 12% to 28% |
| Typical Allocation to HNW Investors | Not disclosed | $25K to $150K per account | N/A |
| Lock-up Period (Employee Shares) | Not disclosed | 180 days standard | N/A |
| IPO Pop (First Day Return, 2026 Avg) | Not disclosed | 8.4% | N/A |
Biotech IPOs in 2026 have underperformed the broader market by 340 basis points through six months post-listing. First-day pops averaged 8.4%, but 60% of issues traded below IPO price by day 90. If you receive an allocation, the decision is whether to sell at open or hold through the lock-up expiration.
What This Means for Your Portfolio
A $100K allocation at a $20 IPO price that pops 8.4% on day one generates $8,400 in unrealized gain. If you sell at the opening bell, that is $8,400 in short-term capital gains taxed at your ordinary income rate. For a California resident in the 37% federal bracket and 13.3% state bracket, net proceeds after tax are $4,227. If you hold six months and the stock trades flat, the gain qualifies for long-term treatment at 20% federal plus 13.3% state, netting $5,589. The hold decision costs you liquidity but saves $1,362 per $100K allocated.
On a $1M portfolio where you allocate $150K to the IPO, the same 8.4% pop and immediate sale generates $12,600 net of tax. Holding through lock-up expiration with no price change nets $16,767. The tax arbitrage is $4,167, but you carry six months of single-stock risk in a biotech name with no revenue.
Scenario Analysis
| Portfolio Size | IPO Allocation (10% to 15% of liquid assets) | Day 1 Pop at 8.4% (Gross) | Net Proceeds if Sold Day 1 (Short-Term Gains) | Net Proceeds if Held 6 Months (Long-Term Gains, Flat Price) | Tax Savings from Hold |
|---|---|---|---|---|---|
| $500K | $50K to $75K | $4,200 to $6,300 | $2,113 to $3,170 | $2,795 to $4,192 | $682 to $1,022 |
| $1M | $100K to $150K | $8,400 to $12,600 | $4,227 to $6,340 | $5,589 to $8,383 | $1,362 to $2,043 |
| $2M | $200K to $300K | $16,800 to $25,200 | $8,453 to $12,680 | $11,178 to $16,767 | $2,725 to $4,087 |
This assumes 37% federal ordinary income rate, 13.3% California state rate, 20% federal long-term capital gains rate, and 3.8% net investment income tax on both. No AMT or phaseout adjustments included. Your state rate will differ.
The table shows the tax benefit of holding through long-term qualification, but does not account for price movement. Biotech IPOs have traded down 11% on average between day 90 and day 180 in 2026. A $150K allocation that drops 11% over six months loses $16,500 in market value, wiping out the $2,043 tax savings and leaving you $14,457 behind the day-one sale.
What To Do With This
If you receive an allocation and the stock pops more than 10% on day one, selling at open locks in a taxable gain but eliminates single-stock concentration risk. If the pop is under 5%, holding six months for long-term treatment makes sense only if you would hold this name in size regardless of tax treatment. Check the S-1 for revenue, burn rate, and pipeline milestones. Scribe has disclosed no commercial product yet. That means you are pricing future approvals, not current cash flow.
Use CalcMoney's Calculate Your After-Tax RSU Proceeds to model the tax drag on your exact allocation size and state rate. Adjust for your federal bracket if you are below 37%.
The Scenario You Have Not Modelled
If you are an employee or early investor subject to the 180-day lock-up, your shares cannot be sold until January 2027 at the earliest. The market will price in lock-up expiration 10 to 15 days before the date. Biotech stocks with employee lock-ups exceeding 40% of float have dropped 9% to 17% in the two weeks before expiration as holders front-run the supply. On a $500K position, that is $45K to $85K in mark-to-market loss before you can exit. If you hold pre-IPO equity, model the expiration date and the float percentage now.
Frequently Asked Questions
Q: What is the typical first-day return for biotech IPOs in 2026?
A: The median first-day return is 8.4%, but 40% of biotech IPOs in 2026 closed below the offer price on day one.
Q: How much of an IPO allocation should a $1M portfolio take?
A: 10% to 15% of liquid assets is standard for HNW allocations, or $100K to $150K, depending on single-stock risk tolerance.
Q: When does the lock-up period expire for employee shares?
A: Standard lock-ups last 180 days from the IPO date, expiring in mid-January 2027 if the IPO prices in late July.
Q: What is the tax difference between selling at IPO and holding six months?
A: On a $100K allocation with an 8.4% day-one pop, selling immediately nets $4,227 after short-term capital gains tax, while holding six months for long-term treatment nets $5,589, a difference of $1,362.
Run the Numbers
Use CalcMoney's Calculate Your After-Tax RSU Proceeds to see your exact figures under the current tax threshold.
Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.
Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.
Put These Numbers to Work
Open a Fidelity brokerage account. $0 commissions, no account minimums, fractional shares available.
Affiliated. We may earn a commission.
Related Guides
Free Tools
Run the actual numbers
Stop estimating. Plug in your numbers and get a precise answer in seconds. Free, no signup required.
Open the Capital Gains Calculator